Plavix

(clopidogrel)

ApprovedSmall molecule

Clopidogrel is a blood thinner that helps prevent blood clots from forming, which is used to reduce the risk of heart attacks and strokes in people with heart disease or who have recently had a stent placed in their arteries.[2] Plavix is currently approved and in use across 67 indications[4].[1]

Plavix is one of 1066 small molecule programs targeting Polycythemia Vera. It is currently in Approved.

Indications

477

Total Trials

Active Trials

1,065

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Polycythemia VeraActive, not recruiting

Cerebral Amyloid AngiopathyActive, not recruiting

Coronary Artery DiseaseApproved

Metabolic SyndromeActive, not recruiting

HIV InfectionActive, not recruiting

Systemic Lupus ErythematosusApproved

Transient Ischemic AttackActive, not recruiting

Cardiovascular DiseaseApproved

Endothelial DysfunctionActive, not recruiting

Renal Artery StenosisActive, not recruiting

Polycythemia VeraPhase 2

Active, not recruiting

Cerebral Amyloid AngiopathyPreclinical

Active, not recruiting

Coronary Artery DiseaseApproved

Approved

Metabolic SyndromeApproved

Active, not recruiting

HIV InfectionPhase 2

Active, not recruiting

Systemic Lupus ErythematosusApproved

Approved

Transient Ischemic AttackPhase 2

Active, not recruiting

Cardiovascular DiseaseApproved

Approved

Endothelial DysfunctionApproved

Active, not recruiting

Renal Artery StenosisApproved

Active, not recruiting

Showing 10 of 64 indications

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Plavix

Sanofi

Approved

2 2

Biaxin

AbbVie

Preclinical

2 3

Tricor

JJagotec

Preclinical

1 4

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 5

Statin

Bristol-Myers Squibb

Preclinical

1 6

Nadroparin

GSK

Preclinical

1 7

Biological Data

UUniversity Hospital, Bordeaux

Preclinical

3 8

Aprotinin

Bayer

Preclinical

1 9

Biological Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

1 10

Conventional

PPopulation Health Research Institute

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalActive, not recruiting

Platelet Inhibition

NCT04654052

Phase 3Recruiting

Acute Coronary Syndrome

NCT06577519

Q2 2027

Post-ApprovalRecruiting

Percutaneous Coronary Intervention

NCT06228456

Q4 2027

Phase 2/3Active, not recruiting

Non-Small Cell Lung Carcinoma

NCT06872541

Post-ApprovalRecruiting

Dual Antiplatelet Therapy

NCT07025148

Q4 2029

Post-ApprovalNot yet recruiting

Cerebral Atherosclerosis

NCT07237308

Clinical

Trials by Indication[1]

Clopidogrel33 trials

Ticagrelor vs. Clopidogrel in Post PCI Patients

Completed·SShiraz University of Medical Sciences·N/A·NCT05858918·476 enrolled

Effects of a Hemp Product on the Pharmacokinetics and Pharmacodynamics of Clopidogrel

Recruiting·WWashington State University·Phase 1·NCT06692933·24 enrolled

Study of Optimal Clopidogrel Duration in Patients Receiving Drug Eluting Stents (SCORE Trial)

Completed·NNorth Texas Veterans Healthcare System·N/A·NCT00781573·167 enrolled

Show 30 more trials

High Clopidogrel Dose Versus Prasugrel and Ticagrelor in High Reactive Stable Patients

Completed·UUniversity of Roma La Sapienza·Phase 3·NCT01543932·81 enrolled

75 or 150 mg Clopidogrel Maintenance Doses Following PCI (ISAR-CHOICE-2)

Completed·DDeutsches Herzzentrum Muenchen·Phase 4·NCT00140465·60 enrolled

Low Maintenance Dose Ticagrelor Versus Clopidogrel in Diabetes Patients Undergoing PCI

Completed·UUniversity of Florida·Phase 4·NCT03437044·40 enrolled

Clopidogrel Reloading in Clopidogrel Resistant Patients With ACS

Completed·SSheba Medical Center·Phase 3·NCT00444132·50 enrolled

Investigation of the Impact of Concomitant Use of Multiple Doses of Clopidogrel With Multiple Doses of Dabigatran Etexilate on the Pharmacokinetic and Pharmacodynamic Parameters in Healthy Male Subjects

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02171598·44 enrolled

Pharmacokinetic Study of Single Doses of Clopidogrel, 75 mg and 300 mg, in Healthy Subjects

Completed· Sanofi logo

Sanofi·Phase 1·NCT01129063·32 enrolled

The Effect of Clopidogrel and Ticagrelor With and Without Acetylsalicylic Acid (ASA) on Hemostatic System Activation at the Site of Plug Formation in Vivo in Man

Completed·MMedical University of Vienna·Phase 2·NCT02120092·89 enrolled

Clopidogrel Resistance and the Possibility of Its Affection

Temporarily not available·—··NCT00839345

A Clinical Study to Assess the Effect of Clopidogrel on the Pharmacokinetics of Selexipag and Its Active Metabolite in Healthy Male Subjects

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT03496506·22 enrolled

Phase 1 Study to Evaluate the Safety and Tolerability of DS-1040b IV Infusion With Clopidogrel in Healthy Subjects

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 1·NCT02560688·22 enrolled

Chewing Clopidogrel in Addition to Regular Oral Clopidogrel Treatment to Improve Platelets Aggregation in Patient With NON ST ELEVATION MI

Unknown status·SSheba Medical Center·Phase 3·NCT00889044·30 enrolled

Hip-Fracture Surgery on Patients in Clopidogrel Therapy

Completed·HHvidovre University Hospital··NCT02391883·356 enrolled

Prasugrel/Clopidogrel Maintenance Dose Washout Study

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 4·NCT01014624·56 enrolled

The EFFect of hIgh Dose ClopIdogrel treatmENT in Patients With Clopidogrel Resistance

Completed·—·Phase 3·NCT01032668·192 enrolled

Uninterrupted Clopidogrel Therapy Before Elective Colonoscopy Will Increase the Risk of Post-polypectomy Bleeding

Completed·—·Phase 4·NCT01806090·216 enrolled

Clopidogrel Prevention of Early Arteriovenous (AV) Fistula Thrombosis

Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 3·NCT03289520·877 enrolled

Bioequivalence Study of Clopidogrel Tablets 300 mg Under Fed Conditions

Completed·—·Phase 1·NCT01621763·68 enrolled

Long Term Safety of Clopidogrel in Neonates/Infants With Systemic to Pulmonary Artery Shunt Palliation

Completed· Sanofi logo

Sanofi·Phase 3·NCT00833703·49 enrolled

CASTLE (Clopidogrel And Serum Troponin Level Elevation)

Completed· Sanofi logo

Sanofi·Phase 3·NCT00716924·155 enrolled

A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants.

Completed· Takeda logo

Takeda·Phase 1·NCT00942175·160 enrolled

VERifynow in DIabetes Non-responsiveness: a Study on Switching From Clopidogrel to Prasugrel

Completed·FFundación Pública Andaluza para la gestión de la Investigación en Sevilla·Phase 4·NCT01684813·65 enrolled

Effect of Prasugrel on Platelets After One Week in Patients Already Taking Clopidogrel After a Cardiac Event

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00356135·139 enrolled

Clopidogrel for Acute Ischaemia of Recent Onset

Completed·—·Phase 4·NCT02776540·188 enrolled

Clopidogrel Resistance and Embolism in Carotid Artery Stenting

Unknown status·SSamsung Medical Center·Phase 3·NCT02133989·86 enrolled

Effect of Naproxen, Aspirin, Celecoxib, or Clopidogrel on the Healing of Stomach and Intestinal Ulcers

Completed·RResearch Associates of New York, LLP·Phase 4·NCT00778193·125 enrolled

CES1 Crossover Trial of Clopidogrel and Ticagrelor

Completed·UUniversity of Maryland, Baltimore·Phase 4·NCT03161678·111 enrolled

Study Evaluating Effect of Esomeprazole, Omeprazole or Lansoprazole on the Pharmacodynamics (PD) and Pharmacokinetics (PK) of Clopidogrel

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT01147588·149 enrolled

Efficacy of Ticagrelor vs Clopidogrel in High-risk NSTE-ACS Patients Undergoing Early PCI

Unknown status·RRenJi Hospital·Phase 4·NCT02201667·444 enrolled

Clopidogrel and Response Variability Investigation Study 2

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT00822666·109 enrolled

Ticagrelor Versus Clopidogrel in Myocardial Salvage in Patients With STEMI Undergoing Primary PCI

Unknown status·TTaipei Veterans General Hospital, Taiwan·Phase 4·NCT02792712·200 enrolled

Acute Coronary Syndrome17 trials

Study to Assess Safety and Efficacy of Ticagrelor (AZD6140) Versus Clopidogrel in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS)

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT01294462·801 enrolled

Half-dose Ticagrelor Overcomes High-dose Clopidogrel in Acute Coronary Syndrome Patients With High On-Clopidogrel Platelet Reactivity

Unknown status·FFirst Affiliated Hospital of Harbin Medical University·Phase 2/3·NCT03062462·80 enrolled

Ticagrelor vs Clopidogrel in Non-ST Elevation Acute Coronary Syndrome Patients Undergoing PCI With Bivalirudin.

Terminated· AstraZeneca logo

AstraZeneca·Phase 4·NCT02052635·34 enrolled

Show 14 more trials

Transition From Ticagrelor to Clopidogrel Following Acute Coronary Syndrome: To Bolus or Not?

Completed·OOttawa Heart Institute Research Corporation·Phase 4·NCT02054663·60 enrolled

Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment For Acute Coronary Syndromes Trial

Completed·LLMU Klinikum·Phase 4·NCT01959451·2,600 enrolled

Efficacy and Safety of BiomatrixTM Stent and 5mg-Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome

Unknown status·—·Phase 4·NCT02446730·1,400 enrolled

A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00391872·18,624 enrolled

Impact of Ticagrelor on the Endothelial Healing Following Drug-eluting Stent Implantation in the Patients With Acute Coronary Syndrome

Terminated·YYonsei University·Phase 4·NCT02037412·148 enrolled

Evaluation of Ticagrelor Anti Platelet and Pleiotropic Effects in Patients Undergoing Percutaneous Coronary Intervention for an Acute Coronary Syndrome

Completed·AAssistance Publique Hopitaux De Marseille·Phase 3·NCT01626534·125 enrolled

Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT01603082·343 enrolled

A Comparison of Antiplatelet Therapies in Asian Subjects With Acute Coronary Syndrome

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00830960·720 enrolled

Vasoactive and Anti-inflammatory Effects of Prasugrel in Acute Coronary Syndrome

Completed·UUniversity of Cologne·Phase 3·NCT01774838·49 enrolled

Trial to Assess the Safety and Effects of Vorapaxar in Japanese Subjects With Acute Coronary Syndrome (P04772; MK-5348-016)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00684203·120 enrolled

A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00699998·9,326 enrolled

TicagRelor Or Clopidogrel in Severe and Terminal Chronic Kidney Disease Patients Undergoing PERcutaneous Coronary Intervention for an Acute Coronary Syndrome.

Completed·AAssistance Publique Hopitaux De Marseille·Phase 3·NCT03357874·259 enrolled

Safety and Efficacy of Ticagrelor vs Clopidogrel in Patients With Acute Coronary Syndrome

Unknown status·AAndalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud··NCT04630288·1,900 enrolled

Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)

Recruiting·JJiangsu vcare pharmaceutical technology co., LTD·Phase 3·NCT06577519·1,000 enrolled

Stroke11 trials

Secondary Prevention of Small Subcortical Strokes Trial

Completed·UUniversity of British Columbia·Phase 3·NCT00059306·3,020 enrolled

Aspirin Resistance and Stroke Risk: Platelet Function Analysis in Patients With Ischemic Events

Completed·NNorthwestern University·Phase 2/3·NCT01586975·93 enrolled

The Influence of CYP2C19 Polymorphism and Clinical Outcomes in Stroke Patients

Completed·NNational Cerebral and Cardiovascular Center, Japan··NCT02711410·518 enrolled

Show 8 more trials

Combining Aspirin With Cilostazol or Clopidogrel in Large-vessel Minor Stroke or TIA

Recruiting·KKafrelsheikh University·Phase 3·NCT06591351·870 enrolled

A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT03766581·2,366 enrolled

MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention

Unknown status·UUniversity of Zurich·Phase 3·NCT03961334·620 enrolled

Cilostazol Stroke Prevention Study for Antiplatelet Combination

Completed·JJapan Cardiovascular Research Foundation·Phase 4·NCT01995370·1,884 enrolled

PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 4·NCT00153062·20,332 enrolled

COMbination of Clopidogrel and Aspirin for Prevention of Early REcurrence in Acute Atherothrombotic Stroke

Completed· Sanofi logo

Sanofi·Phase 4·NCT00814268·358 enrolled

Safety and Efficacy of Aspirin in Stroke Patients With Glucose-6-phosphate Dehydrogenase Deficiency (SAST)

Unknown status·FFirst Affiliated Hospital, Sun Yat-Sen University·Phase 4·NCT04088513·440 enrolled

Combining Aspirin With Ticagrelor or Clopidogrel in Minor Stroke or TIA

Recruiting·KKafrelsheikh University·Phase 3·NCT06591312·900 enrolled

Antiplatelet7 trials

Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- EXtended Antiplatelet Monotherapy (HOST-EXAM)

Completed·SSeoul National University Hospital·Phase 4·NCT02044250·5,530 enrolled

H2 Haplotype and CYP3As Polymorphisms and the Antiplatelet Response to Clopidogrel

Completed·CCentre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal·Phase 4·NCT00433784·120 enrolled

A Phase IV Study of the Onset and Maintenance of the Antiplatelet Effect of Ticagrelor Compared With Clopidogrel in Chinese Patients With ACS

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT01864005·60 enrolled

Show 4 more trials

Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)

Completed·EECRI bv·Phase 3·NCT02833948·231 enrolled

Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS

Completed· Sanofi logo

Sanofi·Phase 3·NCT00335452·25,086 enrolled

P3AMI Antiplatelet Trial

Completed·TThe Royal Wolverhampton Hospitals NHS Trust·Phase 4·NCT02376283·87 enrolled

The Accuracy Of A Novel Platelet Activity Assay In Humans On Antiplatelet Agents: Pharmacodynamics And Comparison With Light Transmission Aggregometry

Completed·—·Phase 1·NCT04822363·112 enrolled

Interaction7 trials

Clopidogrel and Aspirin Interaction Study-2

Completed·PPopulation Health Research Institute·Phase 4·NCT01341964·302 enrolled

Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Clopidogrel

Completed·AAkcea Therapeutics·Phase 1·NCT03392051·18 enrolled

Drug Interaction Study of MGL-3196 With Clopidogrel

Completed· Madrigal Pharmaceuticals logo

Madrigal Pharmaceuticals·Phase 1·NCT04671069·20 enrolled

Show 4 more trials

Interaction Study of Clopidogrel 600/150 mg Given Alone or Concomitantly With Omeprazole 80 mg in Healthy Subjects

Completed· Sanofi logo

Sanofi·Phase 1·NCT01129414·72 enrolled

Investigation of Drug-drug Interaction of HRS-5965 With Clopidogrel and Clarithromycin in Healthy Subjects

Completed·CChengdu Suncadia Medicine Co., Ltd.·Phase 1·NCT07040787·36 enrolled

Interaction Study of Clopidogrel 300/75 mg Given Alone or Concomitantly With Pantoprazole 80 mg in Healthy Subjects

Completed· Sanofi logo

Sanofi·Phase 1·NCT01129427·66 enrolled

A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects

Completed·VViatris Innovation GmbH·Phase 1·NCT03430661·77 enrolled

77 more indications

Coronary Artery Disease6 trials

Effects of Different Doses of Ticagrelor on Platelet Aggregation and Endothelial Function in Diabetic Patients With Stable Coronary Artery Disease

Unknown status·FFirst Affiliated Hospital of Harbin Medical University·Phase 2/3·NCT02889549·60 enrolled

Comparison of Effect & Safety of Clopidogrel Napadisilate With Clopidogrel Bisulfate in Coronary Artery Disease Patients

Completed· Hanmi Pharmaceutical Company Limited logo

Hanmi Pharmaceutical Company Limited·Phase 4·NCT01830491·162 enrolled

An Asian Study to Assess the Properties and Profile of Ticagrelor in Patients With Stable Coronary Artery Disease

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT01118325·146 enrolled

Show 3 more trials

Safety and Efficacy of Low-dose Ticagrelor in Chinese Patients With Stable Coronary Artery Disease

Unknown status·FFirst Affiliated Hospital of Harbin Medical University·Phase 4·NCT02514642·30 enrolled

Clopidogrel High Dose Evaluation for the Patient With Coronary Artery Disease in Japan

Completed·TTakeshi Morimoto·Phase 4·NCT01069302·106 enrolled

Prasugrel Versus High Dose Clopidogrel in Patients With Stable Coronary Artery Disease and High Platelet Reactivity While on Chronic Clopidogrel Treatment

Completed·UUniversity of Patras·Phase 3·NCT01304472·25 enrolled

Percutaneous Coronary Intervention6 trials

Reloading Prasugrel or Clopidogrel on High Platelet Reactivity Before Percutaneous Coronary Intervention

Completed·—·Phase 3·NCT01609647·76 enrolled

Platelet Inhibition of Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients After Elective Percutaneous Coronary Intervention

Completed·PPeking Union Medical College Hospital·Phase 4·NCT02748330·40 enrolled

Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry

Completed·KKaiser Franz Josef Hospital·Phase 3·NCT01515345·1,008 enrolled

Show 3 more trials

STEEL Percutaneous Coronary Intervention

Completed·SSheffield Teaching Hospitals NHS Foundation Trust·Phase 4·NCT02327624·180 enrolled

Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention

Recruiting·UUniversity of Florida·Phase 4·NCT06228456·50 enrolled

Trial in Subjects Undergoing Cardiac Catheterization With Planned Percutaneous Coronary Intervention With Stenting

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00357968·201 enrolled

Myocardial Infarction4 trials

Escalating Clopidogrel by Involving a Genetic Strategy - Thrombolysis In Myocardial Infarction 56

Completed·TThe TIMI Study Group·Phase 2·NCT01235351·335 enrolled

Ticagrelor Versus Clopidogrel in Left Ventricular Remodeling After ST-segment Elevation Myocardial Infarction

Unknown status·GGyeongsang National University Hospital·Phase 4·NCT02224534·326 enrolled

Comparison of Clopidogrel and Ticagrelor on Microvascular Dysfunction in ST-Segment Elevation Myocardial Infarction

Completed·IInha University Hospital·Phase 4·NCT02026219·76 enrolled

Show 1 more trial

Effect of the Repeated Loading Dose of Clopidogrel and High Dose of Clopidogrel Continuous Therapy on the Platelet Aggregation Inhibition in Patients With Myocardial Infarction Undergoing Interventional Treatment.

Withdrawn·FFundacja Ośrodek Badań Medycznych·Phase 4·NCT01636180

Dual Antiplatelet Therapy4 trials

Reversal of Dual Antiplatelet Therapy With Cold Stored Platelets

Unknown status·BBloodworks·Phase 1/2·NCT03787927·60 enrolled

Statin and Dual Antiplatelet Therapy to Prevent Early Neurological Deterioration in Branch Atheromatous Disease

Completed·—·Phase 2·NCT04824911·376 enrolled

Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2)

Recruiting·UUniversity of Florida·Phase 4·NCT07025148·40 enrolled

Show 1 more trial

Safety and Efficacy of Six Months Dual Antiplatelet Therapy After Drug-Eluting Stenting

Unknown status·DDeutsches Herzzentrum Muenchen·Phase 4·NCT00661206·4,005 enrolled

Ischemic stroke4 trials

Ticagrelor Versus Clopidogrel in Large Vessel Ischemic Stroke

Completed·KKafrelsheikh University·Phase 3·NCT06120725·580 enrolled

Efficacy of Colchicine in Preventing Recurrent Stroke in the Patients With Acute Atherothrombotic Ischemic Stroke During Hospitalization

Unknown status·MMikhail Zykov·Phase 4·NCT06102720·200 enrolled

Evaluation of the Biological Response to Clopidogrel in Patients With Ischemic Stroke

Completed·—··NCT01955642·91 enrolled

Show 1 more trial

A REAl-life Study on Short-term DAPT in Patients With Ischemic Stroke or TIA

Completed·UUniversity of L'Aquila··NCT05476081·2,239 enrolled

Platelet Reactivity3 trials

Downstream Molecular Signals of P2Y12 Receptors in Hyporeactive Patients Under Clopidogrel Treatment A Possible Mechanism of HOTPR(High On-Treatment Platelet Reactivity)

Completed·TTaipei City Hospital··NCT03190005·35 enrolled

Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI)

Terminated· Eli Lilly logo

Eli Lilly·Phase 2·NCT00910299·423 enrolled

Ticagrelor Versus High-dose Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After PCI

Withdrawn·NNanjing First Hospital, Nanjing Medical University·Phase 3·NCT03078465

Antiplatelet Therapy3 trials

Platelet-dependent Thrombosis: a Placebo-controlled Trial of Antiplatelet Therapy (Clopidogrel)

Completed·NNewcastle-upon-Tyne Hospitals NHS Trust·Phase 4·NCT00728156·90 enrolled

Bedside Testing of CYP2C19 Gene for Treatment of Patients With PCI With Antiplatelet Therapy

Unknown status·IImam Abdulrahman Bin Faisal University·Phase 4·NCT01823185·1,500 enrolled

Tailored Antiplatelet Therapy Following PCI

Completed·MMayo Clinic·Phase 4·NCT01742117·5,276 enrolled

Atrial Fibrillation3 trials

Escalated Single Platelet Inhibition for One Month Plus NOAC in Patients With Atrial Fibrillation and ACS Undergoing PCI

Unknown status·LLudwig-Maximilians - University of Munich·Phase 4·NCT04981041·2,334 enrolled

Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 3·NCT02866175·1,506 enrolled

Efficacy and Safety of Aspirin and Clopidogrel in the Atrial Fibrillation With Low or Moderate Stroke Risk

Unknown status·—·Phase 3·NCT02960126·1,500 enrolled

Platelet Inhibition3 trials

Effect of Platelet Inhibition According to Clopidogrel Dose in Patients With Body Mass Index ≥ 27

Completed·LLes Laboratoires des Médicaments Stériles·Phase 4·NCT01509365·116 enrolled

VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome

Active, not recruiting·FFundación EPIC·Phase 4·NCT04654052·634 enrolled

Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.

Terminated· Novartis logo

Novartis·Phase 3·NCT00385138·5,364 enrolled

Platelet Function3 trials

Effect of Prasugrel Versus Clopidogrel on Platelet Function After Bivalirudin Cessation

Completed·TTufts Medical Center·Phase 4·NCT01789814·24 enrolled

Reproducibility and Comparison of Platelet Function Assays With Aspirin and Clopidogrel (MK-0000-167)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT01108588·15 enrolled

Platelet Function Monitoring in Patients Treated With Clopidogrel at the Time of Primary Percutaneous Coronary Angioplasty

Completed·OOttawa Heart Institute Research Corporation·Phase 2/3·NCT00827346·100 enrolled

Coronary Artery Bypass3 trials

Dual Antiplatelet Therapy in Patients With Aspirin Resistance Following Coronary Artery Bypass Grafting

Completed·UUniversity of Zagreb·Phase 4·NCT01159639·200 enrolled

Effect of Clopidogrel (Plavix) on Postoperative Bleeding in Patients Undergoing Coronary Artery Bypass Surgery.

Completed·CCatharina Ziekenhuis Eindhoven·Phase 4·NCT00724880·135 enrolled

Aspirin and Plavix Following Coronary Artery Bypass Grafting

Terminated·AAhmad Slim·Phase 4·NCT01158703·20 enrolled

Endothelial Function3 trials

Hunting for the Off-Target Properties of Ticagrelor on Endothelial Function in Humans (HI-TECH)

Completed·EErasmus Medical Center·Phase 4·NCT02587260·54 enrolled

ComparisoN of ticAgrelor vs. Clopidogrel in endoTHeliAl Function of COPD patieNts

Completed·UUniversity Hospital of Ferrara·Phase 2·NCT02519608·44 enrolled

The Effect of Ticagrelor or Clopidogrel on Endothelial Function During Acute and Chronic Treatment

Completed·MMichael Wolzt, Prof. MD·Phase 4·NCT02580149·24 enrolled

ART2 trials

Diabetic Artery Obstruction: is it Possible to Reduce Ischemic Events With Cilostazol?

Completed·UUniversity of Ioannina·Phase 4·NCT02983214·826 enrolled

Study of Effects of Ticagrelor on Microparticles and Micro-RNA in NSTE-ACS

Terminated·—·Phase 4·NCT02071966·55 enrolled

Safety and Efficacy2 trials

Safety and Efficacy of Low-Dose Ticagrelor in Chinese Patients With NSTE-ACS

Unknown status·FFirst Affiliated Hospital of Harbin Medical University·Phase 3·NCT02415803·75 enrolled

A Phase 2 Safety and Efficacy Study of PRT060128, a Novel Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent PCI

Completed·PPortola Pharmaceuticals·Phase 2·NCT00751231·652 enrolled

Fasting Conditions2 trials

Bioequivalence Study of Clopidogrel Tablets 75 mg of Dr. Reddy's Under Fasting Conditions

Completed·—·Phase 1·NCT01506713·53 enrolled

Bioequivalence Study of Clopidogrel Tablets 300 mg Under Fasting Conditions

Completed·—·Phase 1·NCT01621750·68 enrolled

Antithrombotic2 trials

Resistance to Antithrombotic Therapy

Completed·MMedical University of Vienna·N/A·NCT00858715·46 enrolled

Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI

Recruiting·MMedical University of Gdansk·Phase 4·NCT04695106·2,230 enrolled

Type 2 Diabetes Mellitus2 trials

Multiple Escalating Oral Doses Study of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus

Completed· Pfizer logo

Pfizer·Phase 1·NCT04305587·66 enrolled

Comparison of TIcagrelor and Clopidogrel in Patients With Coronary Artery diseaSe and Type 2 Diabetes Mellitus (TICS-DM)

Unknown status·SSpanish Society of Cardiology·Phase 4·NCT02457130·30 enrolled

Stent Implantation2 trials

Effect of Different Anti-platelet Strategies on the Long-term Outcome After Sirolimus Drug-eluting Stent Implantation

Unknown status·SSir Run Run Shaw Hospital·N/A·NCT01233167·5,232 enrolled

Short-Term Dual Antiplatelet and Maintenance CloPidogrel Therapy After Drug-Eluting Stent Implantation

Terminated·CCHEOL WHAN LEE, M.D., Ph.D·Phase 4·NCT02494284·364 enrolled

Peripheral Artery Disease2 trials

Residual Platelet Activity In Advanced Peripheral Artery Disease

Unknown status·UUniversity of Roma La Sapienza·Phase 4·NCT01627431·410 enrolled

Adenosine-induced Myocardial Blood Flow in Peripheral Artery Disease Patients

Withdrawn· AstraZeneca logo

AstraZeneca·Phase 4·NCT02121288

Diabetes Mellitus2 trials

Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3)

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00642174·35 enrolled

Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus

Completed·UUniversity of Florida·Phase 4·NCT02548650·66 enrolled

Atorvastatin2 trials

Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting

Unknown status·—·Phase 4·NCT01572623·150 enrolled

The Inhibition of Platelet Antiaggregating Activity of Clopidogrel by Atorvastatin Detected by Erythromycin Breath Test: a Metabolic Inhibition of Hepatic Cytochrome P450-3A

Unknown status·NNational Center for Research Resources (NCRR)·N/A·NCT00004564

Efficacy and Safety2 trials

Efficacy and Safety of Low-dose Ticagrelor

Completed·FFirst Affiliated Hospital of Harbin Medical University·Phase 2/3·NCT03381742·3,043 enrolled

Efficacy and Safety Study of Ticagrelor

Unknown status·GGeneral Hospital of Chinese Armed Police Forces·Phase 3·NCT01812330·180 enrolled

Thrombolysis2 trials

Ticagrelor for PCI Post Thrombolysis

Completed·UUnity Health Toronto·Phase 3·NCT01930591·140 enrolled

Comparing Ticagrelor and Clopidogrel Pharmacodynamics After Thrombolysis

Withdrawn·—·Phase 4·NCT02048085

Transient Ischemic Attack2 trials

Sanchitongtshu Plus Asprine for Minor Ischemic Stroke or Transient Ischemic Attack: A Randomized Double-blind Study

Unknown status·XXinhua Hospital, Shanghai Jiao Tong University School of Medicine·N/A·NCT02975076·120 enrolled

Fast Assessment of Stroke and Transient Ischemic Attack to Prevent Early Recurrence (FASTER)

Completed·UUniversity of Calgary·Phase 2/3·NCT00109382·500 enrolled

Intraoperative1 trial

Evaluation of Antiplatelet Effects and Safety of Intraoperative Administration of Ticagrelor Versus Clopidogrel

Unknown status·YYongjian Wu·Phase 4·NCT02513004·60 enrolled

Ischemia1 trial

Establishing the Microcirculatory Effects of Ticagrelor on Tissue Perfusion in Critical Limb Ischemia

Terminated·TThe Cleveland Clinic·Phase 2/3·NCT02230527·46 enrolled

Cerebral Atherosclerosis1 trial

BEACON-AA: Apixaban With or Without Clopidogrel in Stroke Patients With Atrial Fibrillation and Cerebral Atherosclerosis

Not yet recruiting·YYonsei University·Phase 4·NCT07237308·586 enrolled

Atherosclerotic Plaque1 trial

Comparison of Clopidogrel Versus Ticagrelor Therapy for Atherosclerotic Plaque Inflammation

Completed·CCHEOL WHAN LEE, M.D., Ph.D·Phase 4·NCT01905566·50 enrolled

Trial1 trial

Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis II

Completed·—·Phase 4·NCT00130039·457 enrolled

Elderly1 trial

The Elderly ACS II Trial

Completed·AAzienda USL Reggio Emilia - IRCCS·Phase 4·NCT01777503·1,457 enrolled

Randomized Controlled Trial1 trial

TADCLOT- a Double Blind Randomized Controlled Trial

Completed·NNational Institute of Cardiovascular Diseases, Pakistan·Phase 3·NCT06318481·2,200 enrolled

Asthma1 trial

Effect of Clopidogrel on Allergen Challenge in Asthma

Completed·UUniversity of Southampton·Phase 2·NCT01955512·24 enrolled

Tics1 trial

Study to Assess Pharmacokinetics, Pharmacodynamics and Safety of Tiprogrel in Healthy Subjects

Completed·TTianjin Institute of Pharmaceutical Research Co., Ltd·Phase 1·NCT06584812·14 enrolled

Type 2 Diabetes1 trial

Clopidogrel Versus Ticagrelor in Type-2 Diabetes

Completed·—·Phase 4·NCT02742987·42 enrolled

COVID-191 trial

Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19

Completed·UUniversity of Milan·Phase 2·NCT04368377·5 enrolled

Hemodialysis1 trial

Prasugrel Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Undergoing Chronic Hemodialysis

Completed·UUniversity of Patras·Phase 3·NCT01155765·70 enrolled

Chronic Total Occlusion1 trial

TIcaGrEloR and ABSORB Bioresorbable Vascular Scaffold Implantation for Recovery of Vascular Function After Successful Chronic Total Occlusion Recanalization

Completed·HHospital Clinic of Barcelona·Phase 4·NCT02211066·59 enrolled

Thrombosis1 trial

Ex Vivo Human Thrombosis Chamber Study

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00935506·15 enrolled

Miscarriage1 trial

Aspirin Versus Clopidogrel Effect on Uterine Blood Flow in Women With Unexplained Recurrent Miscarriages

Unknown status·—·Phase 2/3·NCT01635426·32 enrolled

Vascular Disease1 trial

Anti-Inflammatory and Anti-Platelet Effect of Clopidogrel and Aspirin vs Aspirin Alone in Symptomatic Polyvascular Disease and in Patients With Multiple Recurrent Cardiovascular Events

Unknown status·—·Phase 3·NCT00775762·213 enrolled

Heart Attack1 trial

Which Therapy for Acute Heart Attacks? (The WEST Study)

Completed·UUniversity of Alberta·Phase 2/3·NCT00121446·300 enrolled

Metabolic Syndrome1 trial

PROCLAIM: Study Examining Effects of Clopidogrel Compared to Placebo on Inflammation in Subjects With Metabolic Syndrome

Completed· Sanofi logo

Sanofi·Phase 4·NCT00296803·216 enrolled

Antithrombotic Agents1 trial

OPTImal Management of Antithrombotic Agents: OPTIMA-2 Trial

Completed·TThe First Affiliated Hospital with Nanjing Medical University·Phase 4·NCT01955200·1,724 enrolled

Necrosis1 trial

ALBION "Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis"

Completed· Sanofi logo

Sanofi·Phase 2·NCT00360386·110 enrolled

Peripheral Arterial Disease1 trial

CASPAR : Clopidogrel and Acetyl Salicylic Acid in Bypass Surgery for Peripheral ARterial Disease

Completed· Sanofi logo

Sanofi·Phase 3·NCT00174759·1,460 enrolled

Pancreatic Adenocarcinoma1 trial

Safety and Efficacy of Clopidogrel in Locally Advanced and Metastatic Pancreatic Adenocarcinoma Treated With Chemotherapy

Terminated·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT02404363·39 enrolled

Renal artery stenosis1 trial

Zainidip in Renal Artery Stenosis

Completed·LLee's Pharmaceutical Limited·Phase 4·NCT02594410·149 enrolled

Endotoxemia1 trial

Ticagrelor in Human Endotoxemia Response to Human Endotoxemia

Completed·RRadboud University Medical Center·N/A·NCT02612480·40 enrolled

Aneurysm1 trial

Comparison of Two Different Antiplatelet Preparations for an Unruptured Intracranial Aneurysm

Completed·SSeoul National University Hospital·Phase 4·NCT03581409·198 enrolled

Ventricular Function1 trial

A Multicenter Trial to Assess the MIcrovascular Integrity and Left Ventricular Function Recovery After Clopidogrel or TicagrelOr Administration, in Patients With STEMI Treated With Thrombolysis - The 'MIRTOS' Study

Completed·HHellenic Cardiovascular Research Society·Phase 3·NCT02429271·336 enrolled

Complication1 trial

Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery.

Active, not recruiting·PPetrovsky National Research Centre of Surgery··NCT07358416·500 enrolled

P2Y12 Inhibitor1 trial

P2Y12 Inhibitor Monotherapy Versus Extended DAPT in Patients Treated With Bioresorbable Scaffold

Terminated·SSamsung Medical Center·Phase 4·NCT03119012·25 enrolled

Single Antiplatelet Therapy1 trial

Ticagrelor Single Antiplatelet Therapy in Patients With High Risk of Bleeding After DCB for Coronary Small Vessel Disease

Unknown status·FFu Wai Hospital, Beijing, China·Phase 4·NCT06088433·292 enrolled

Staphylococcus Aureus Bacteremia1 trial

Adjuvant Clopidogrel in Staphylococcus Aureus Bacteremia

Not yet recruiting·FFundación Pública Andaluza para la gestión de la Investigación en Sevilla·Phase 2·NCT07384702·230 enrolled

Headache1 trial

Clopidogrel For the Prevention of New Onset Migraine Headache Following Transcatheter Closure of Atrial Septal Defects

Completed·LLaval University·Phase 4·NCT00799045·220 enrolled

Immune Response1 trial

The Antiplatelet and Immune Response Trial

Completed·SSheffield Teaching Hospitals NHS Foundation Trust·Phase 4·NCT01846559·30 enrolled

Acute Myocardial Infarction1 trial

Antiplatelet Therapy Effect on Extracellular Vesicles in Acute Myocardial Infarction

Completed·MMedical University of Warsaw·Phase 4·NCT02931045·60 enrolled

Pregnancy1 trial

Comparison Between Effect of Enoxaparin and Clopidogrel on Improving Pregnancy Rate in ICSI

Unknown status·—·Phase 4·NCT02696330·150 enrolled

Transcatheter Aortic Valve Replacement1 trial

Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes

Terminated· Bayer logo

Bayer·Phase 3·NCT02556203·1,653 enrolled

ESRD1 trial

ONSET and OFFSET of Ticagrelor in ESRD

Completed·KKyunghee University Medical Center·Phase 3·NCT02163954·16 enrolled

Optical Coherence Tomography1 trial

Optical Coherence Tomography to Evaluate Ticagrelor and Clopidogrel

Completed·NNanjing First Hospital, Nanjing Medical University·Phase 4·NCT02140801·352 enrolled

Drug1 trial

SMart Angioplasty Research Team: CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 3

Completed·JJoo-Yong Hahn·Phase 4·NCT04418479·5,506 enrolled

Treatment1 trial

Optimal Duration of DAPT Following Treatment With Endeavor (Zotarolimus-eluting Stent) in Real-world Japanese Patients

Completed·AAssociations for Establishment of Evidence in Interventions·Phase 4·NCT01325935·1,187 enrolled

Efficacy1 trial

Efficacy of Activated Recombinant Human Factor VII in Healthy Volunteers Treated for Punch Biopsy Mediated Bleeding

Terminated· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT01561950·91 enrolled

Intensive Care Unit1 trial

High "on Treatment" Platelet Reactivity in the Intensive Care Unit

Unknown status·MMedical University of Vienna·Phase 2·NCT02285751·200 enrolled

Oral Anticoagulation1 trial

Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI

Completed·UUniversity of Florida·Phase 4·NCT04483583·81 enrolled

Percutaneous Coronary Intervention (PCI)1 trial

Prasugrel Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Post Percutaneous Coronary Intervention (PCI).

Completed·UUniversity of Patras·Phase 3·NCT01109784·70 enrolled

Non-Small Cell Lung Carcinoma1 trial

Evaluation of Platelet Aggregability in Patients with Non-small Cell Lung Carcinomas

Active, not recruiting·UUniversity of Sao Paulo·Phase 2/3·NCT06872541·100 enrolled

Antiplatelet Drug1 trial

Comparison of Loading Strategies With Antiplatelet Drugs in Patients Undergoing Elective Coronary Intervention

Terminated·LLMU Klinikum·Phase 4·NCT02548611·795 enrolled

Microcirculation1 trial

Comparing Ticagrelor Versus Clopidogrel on Microcirculation

Completed·—·N/A·NCT02618733·120 enrolled

Endothelial Dysfunction1 trial

Ramipril and Clopidogrel in Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Type 2 Diabetes and Diabetic Nephropathy

Unknown status·—·Phase 4·NCT01743014·60 enrolled

Mitral regurgitation1 trial

Impact of Medical and Surgical Therapy on Functional Mitral Regurgitation

Completed·—·N/A·NCT00224809·250 enrolled

Tumors1 trial

Anti-platelet + Pembro for H&N Tumors

Completed·MMedical University of South Carolina·Phase 1·NCT03245489·20 enrolled

Oral1 trial

Dose-escalation, Repeated and Single Oral Dosing Study

Terminated· IlDong Pharmaceutical Co Ltd logo

IlDong Pharmaceutical Co Ltd·Phase 1·NCT02419820·104 enrolled

Exercise1 trial

Change in Exercise Capacity as Measured by Peak Oxygen Uptake After CTO PCI

Terminated·HHenry Ford Health System··NCT02499666·15 enrolled

Occlusion1 trial

The Carotid and Middle Cerebral Artery Occlusion Surgery Study

Completed·XXuanwu Hospital, Beijing·Phase 3·NCT01758614·330 enrolled

Unspecified4 trials

TIcagrelor in Rotational Atherectomy to Reduce TROPonin Enhancement

Completed·UUniversity Hospital, Toulouse·Phase 4·NCT02505399·180 enrolled

The 3 Years vs 1 Year DAPT After XINSORB BRS Implantation

Not yet recruiting·SShanghai Zhongshan Hospital·Phase 4·NCT04501900·2,106 enrolled

Simplified Anti-Thrombotic Therapy for FFR

Completed·OOdessa Heart Institute·N/A·NCT02384070·300 enrolled

Show 1 more trial

Cilostazol and Endothelial Progenitor Cell

Unknown status·GGyeongsang National University Hospital·Phase 4·NCT04407312·60 enrolled

Regulatory

FDA Approval Timeline[5]

Nov 17, 1997

PLAVIX

NDA NDA020839

Sources

References

[1]
ClinicalTrials.gov — 477 trial records for clopidogrel. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Plavix drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — clopidogrel compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for clopidogrel. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA020839). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Purinergic Receptor P2Y12 Antagonist[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Sanofi